Core Viewpoint - Shanghai Pharmaceuticals has announced the results of the third exercise period of its 2019 A-share stock option incentive plan, indicating that no stock options were exercised during this period [2][3][4]. Group 1: Stock Option Incentive Plan - The number of stock options available for exercise in the third period is 680,000, with the exercise period running from February 8, 2025, to February 7, 2026 [2]. - No stock options were exercised by the incentive recipients during the third exercise period [3]. - The unexercised stock options from the third exercise period will be canceled by the company [4]. Group 2: Approval Process for the Incentive Plan - The stock option incentive plan underwent several approval processes, including meetings of the board and supervisory board, and received approval from the Shanghai State-owned Assets Supervision and Administration Commission [5][6][7]. - The first grant of stock options was confirmed on December 19, 2019, with subsequent adjustments made to the list of incentive recipients and the number of options granted [10][11]. Group 3: Impact on Financials - As of the end of the third exercise period, the total share capital of the company is 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status or operating results [18].

Group 1: Board Election Announcement - The company announced the election of Mr. Zhao Yong as the employee representative director of the eighth board of directors, following the approval of the employee representative conference held on February 11, 2026 [1][3] - Mr. Zhao Yong meets the qualifications and conditions for the position as stipulated by relevant laws and the company's articles of association [1] - The number of directors who are also senior management and those who are employee representatives does not exceed half of the total number of directors, complying with legal requirements [1] Group 2: Stock Option Incentive Plan - The company reported that 680,000 stock options from the third exercise period of the 2019 A-share stock option incentive plan were available for exercise from February 8, 2025, to February 7, 2026 [5] - No stock options were exercised during the third exercise period, and the unexercised options will be canceled by the company [6][17] - The total share capital of the company as of the end of the third exercise period was 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status [22] Group 3: Approval of Raw Material Drug - The company announced that its subsidiary, Shanghai Pharmaceutical Kangli, received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride [23][24] - Tamsulosin hydrochloride is a third-generation selective long-acting α1 blocker used for treating benign prostatic hyperplasia (BPH) [25] - The company has invested approximately RMB 1.5 million in research and development for this drug, which is expected to enhance its market presence [26]

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the production of Tamsulosin Hydrochloride raw material by the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice for the marketing application of Tamsulosin Hydrochloride [1] - Tamsulosin Hydrochloride is a third-generation highly selective long-acting α1 inhibitor, used for the treatment of benign prostatic hyperplasia [1] Group 2: Product Background - The drug was developed by Japan's Yamanouchi Pharmaceutical and was approved for marketing by the U.S. Food and Drug Administration in July 1992 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval was granted to Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd. [1] - The company has invested approximately RMB 1.5 million in research and development for Tamsulosin hydrochloride [1] - The drug is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] Group 2: Regulatory and Market Implications - The approval indicates that the raw material meets the regulatory requirements for domestic drug registration, allowing it to be sold in the domestic market [1] - This experience will be valuable for the company in future raw material drug applications [1] - The approval is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval for Tamsulosin hydrochloride indicates that the raw material meets domestic drug registration requirements and can be sold in the domestic market [1] - The company has invested approximately RMB 1.5 million in research and development for this drug [1] - The approval process has provided valuable experience for the company in future raw material drug applications [1] Group 2: Product Information - Tamsulosin hydrochloride is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in July 2024, which was accepted [1] Group 3: Financial Impact - The approval of Tamsulosin hydrochloride is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced the election of Mr. Zhao Yong as the employee director of the company's eighth board of directors during the second joint meeting of the third employee representative assembly scheduled for February 11, 2026 [1] Group 1 - Mr. Zhao Yong was elected as the employee director of the eighth board of directors [1] - The election was conducted in accordance with the company's shareholder meeting procedures [1] - Mr. Zhao's term will last from the date of election until the end of the eighth board's term [1]

格隆汇2月11日丨上海医药(02607.HK)宣布，于2026年2月11日召开的第三届职工代表大会第二次联席会 议上，赵勇获选举为公司第八届董事会职工董事，赵勇与经公司股东会选举产生的董事共同组成公司第 八届董事会，任期自公司职工代表大会选举之日起至第八届董事会任期届满之日止。 ...

Core Viewpoint - Shanghai Pharmaceuticals (02607) announced the election of Mr. Zhao Yong as the employee director of the company's eighth board of directors during the second joint meeting of the third employee representative assembly scheduled for February 11, 2026 [1] Group 1 - Mr. Zhao Yong was elected as the employee director of the eighth board of directors [1] - The term of Mr. Zhao Yong will last from the date of election by the employee representative assembly until the end of the eighth board's term [1] - Mr. Zhao Yong will work alongside directors elected by the company's shareholders to form the eighth board of directors [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三 個行權期自主行權結果公告》、《上海醫藥集團股份有限公司關於鹽酸坦索羅辛原料藥上市申 請獲得批准的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 2 月 12 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生； ...

(股份代碼: 02607) 上海醫藥集團股份有限公司 董事名單及其角色和職能 Shanghai Pharmaceuticals Holding Co., Ltd. * 於 2026 年 2 月 11 日，上海醫藥集團股份有限公司董事會(「董事會」)成員列示如下： （於中華人民共和國註冊成立的股份有限公司） 執行董事: 楊秋華先生（董事長） 沈波先生 李永忠先生 董明先生 非執行董事: 張文學先生 霍文遜先生（召集人） 沈波先生 顧朝陽先生 萬鈞女士 審計委員會: 顧朝陽先生（召集人） 霍文遜先生 王忠先生 薪酬與考核委員會: 趙勇先生 獨立非執行董事: 顧朝陽先生 霍文遜先生 王忠先生 萬鈞女士 戰略委員會: 楊秋華先生（召集人） 張文學先生 王忠先生 提名委員會: 職工董事: 王忠先生（召集人） 楊秋華先生 顧朝陽先生 中國上海，2026 年 2 月 11 日 * 僅供識別 ...